How should I use Opdualag(Nivolumab and Relatlimab)?

This section details the recommended dosage and method of administration for OPDUALAG.

Dosage and Administration

The recommended dosage for eligible patients is 480 mg of nivolumab and 160 mg of relatlimab administered as an intravenous infusion every 4 weeks. The infusion should be given over 30 minutes through a line equipped with a sterile, low protein-binding filter. Treatment continues until disease progression or unacceptable toxicity occurs. Dosage modifications, including withholding or permanent discontinuation, are required for specific adverse reactions, particularly immune-mediated adverse events, based on their severity as graded by standardized criteria. The product can be administered diluted or undiluted.